Insider · CIK 0001862930
Filip Janku
Files at GLUE (Monte Rosa Therapeutics, Inc.). First filing Jan 5, 2026, latest Jul 1, 2026.
In brief
Filip Janku files SEC Form 4 as officer at GLUE (Monte Rosa Therapeutics, Inc.). Since Jan 5, 2026, Filip Janku has reported 0 open-market buys worth $0 and 5 open-market sells worth $1.4M, the latest filed on Jul 1, 2026.
A track record needs three past buys with six months of prices behind them; Filip Janku has 0, so none is measured yet.
The newest scored trade: sold $132k of GLUE on Jun 30, 2026, filed Jul 1, 2026, scored 6 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $1.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GLUE: Monte Rosa Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 6Weak | Monte Rosa Therapeutics, Inc. | $132k 5,407 shares | -8% | +478% from low-4% from high | |
| 6Weak | Monte Rosa Therapeutics, Inc. | $138k 6,000 shares | -9% | +470% from low-6% from high | |
| 38Weak | Monte Rosa Therapeutics, Inc. | $882k 41,845 shares | -58% | +394% from low-18% from high | |
| 47Moderate | Monte Rosa Therapeutics, Inc. | $179k 9,189 shares | -12% | +427% from low-23% from high | |
| 37Weak | Monte Rosa Therapeutics, Inc. | $48k 3,155 shares | -4% | +289% from low-23% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 30, 2026 | GLUE Monte Rosa Therapeutics, Inc. | 5,407 0.01% of outstanding | $129k | Jun 30, 2026 | $1.0M |
| Jun 29, 2026 | GLUE MONTE ROSA THERAPEUTICS INC | 6,000 0.01% of outstanding | $134k | Jun 29, 2026 | $882k |
| Jun 24, 2026 | GLUE MONTE ROSA THERAPEUTICS INC | 30,000 0.04% of outstanding | $621k | Jun 24, 2026 | $240k |
| Jun 23, 2026 | GLUE MONTE ROSA THERAPEUTICS INC | 11,845 0.01% of outstanding | $221k | Jun 23, 2026 | none |
| Feb 23, 2026 | GLUE MONTE ROSA THERAPEUTICS, INC. | 9,189 0.01% of outstanding | $179k | Feb 23, 2026 | $48k |
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,407 | $13.41 | $73k | 66,019 | Jul 1, 2026 |
| Jun 30, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,407 | $24.50 | $132k | 60,612 | Jul 1, 2026 |
| Jun 30, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,407 | $0.00 | $0 | 81,093 | Jul 1, 2026 |
| Jun 29, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,000 | $7.56 | $45k | 65,992 | Jun 30, 2026 |
| Jun 29, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,000 | $22.95 | $138k | 59,992 | Jun 30, 2026 |
| Jun 29, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 60,000 | Jun 30, 2026 |
| Jun 23, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,000 | $7.56 | $45k | 71,837 | Jun 25, 2026 |
| Jun 23, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -11,845 | $20.22 | $240k | 59,992 | Jun 25, 2026 |
| Jun 24, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +30,000 | $7.56 | $227k | 89,992 | Jun 25, 2026 |
| Jun 24, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -30,000 | $21.42 | $643k | 59,992 | Jun 25, 2026 |
| Jun 23, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 96,000 | Jun 25, 2026 |
| Jun 24, 2026 | GLUE Monte Rosa Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 66,000 | Jun 25, 2026 |
| Feb 23, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock | -9,189 | $19.50 | $179k | 65,837 | Feb 24, 2026 |
| Jan 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Common Stock | +31,000 | - | - | 78,181 | Jan 5, 2026 |
| Jan 5, 2026 | GLUE Monte Rosa Therapeutics, Inc. | SOpen-market sale Common Stock | -3,155 | $15.17 | $48k | 75,026 | Jan 5, 2026 |
| Jan 2, 2026 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +139,000 | $0.00 | $0 | 139,000 | Jan 5, 2026 |
| Jan 2, 2025 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Common Stock | +36,000 | - | - | 45,189 | Jan 6, 2025 |
| Jan 2, 2025 | GLUE Monte Rosa Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +161,000 | $0.00 | $0 | 161,000 | Jan 6, 2025 |
Questions about Filip Janku
Answered from the filings on this page, as of the latest one.
Is Filip Janku buying or selling?
In the last 12 months Filip Janku reported 0 open-market buys worth $0 and 5 open-market sells worth $1.4M on SEC Form 4; the latest was sold $132k of GLUE on Jun 30, 2026. Grants, option exercises and tax withholding are not counted.
How did Filip Janku's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Filip Janku has 0.
Where does Filip Janku file Form 4?
Filip Janku has filed Form 4 at GLUE (Monte Rosa Therapeutics, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.